YAP/TAZ-TEAD antagonist - FogPharma
Alternative Names: YAP/TAZ-TEAD antagonistLatest Information Update: 02 Apr 2024
At a glance
- Originator FogPharma
- Developer FogPharma; Harvard University
- Class Antineoplastics; Peptides
- Mechanism of Action Protein interaction domain and motif inhibitors; TEA domain transcription factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer